ESG activities Trianon’s sustainability agenda focuses on five areas, based on a selection of the U...
We revise down our comparable EBITDA estimates by 8% for 2022 and 4% for 2023, reflecting the lowere...
Aspo actively continues its investigation into strategic alternatives for its operations in Russia, ...
Redeye initiates coverage of SenzaGen, a Swedish commercial-stage MedTech company offering high-perf...
Sales still held back by inventory build-up at distributors Weakness to continue in Q2 but potentia...
23% organic growth for record Q1 sales Margins held back by component situation Trades at 11-8x our...
Redeye comments on yesterday’s announcement regarding the outcome of Annexin’s TO3 warrant program.
Redeye sees a Q1 report with the increased transparency regarding Bidbrain as the highlight.
Redeye leaves its comments on Idogen following the report for the first quarter of 2022.
Redeye returns with a more in-depth take on the Q1 report and discusses some of the key take-aways a...
Q1 sales -13% vs cons, order intake +17% vs ABGSC The company expect supply chain challenges also in...
Redeye comments on Invisio’s Q1 results which came in weaker than expected mainly due to delay in de...
Redeye comments on Energy Save’s follow-up order from Skanska OY and the new partnership with AQ Gro...
Sales +10% vs. ABG & adj. EBIT margin 2% vs. ABG 4% Small negative GM and positive NRI adjustments ...
Sales in line with better instrument deliveries Strong orderbook but supply and geopolitical uncerta...
Aspo’s Q1 results clearly topped estimates, however the previous full-year guidance is retained for ...
Eltel’s Q1 top line was close to estimates, but the war and unforeseen inflation hit bottom line har...
Redeye reevaluates Alligator Bioscience ahead of its first efficacy readout from mitazalimab later t...
Bolagets hyresintäkter är inflationssäkrade, och SBB arbetar med fasta räntor under långa löptider v...
Temporary cost savings behind strong profitability in Q2 Positive L-T revisions from acquisitions Un...
